SVF
Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

FGFs/FGFRs and neuroinflammatory diseases: mechanism, drug therapies and delivery systems

Wang J., Xing L., Song Y., Yang Y., Zhang Y., Ma H.

Narrative Review on Neuroinflammation, Chronic Inflammation, published in J Adv Res (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Adv Res (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40518115
PMCID
PMC12684962
DOI
10.1016/j.jare.2025.06.024
Citations
5

Abstract (original English)

Background Fibroblast Growth Factors and Fibroblast Growth Factor Receptors (FGFs/FGFRs) constitute a complex and diverse signaling system crucial in various biological processes, such as cell proliferation, differentiation, migration, and survival. Dysregulation of the FGFs/FGFRs system plays a key role in the progression of neurological diseases through the neuroinflammatory process. FGFs/FGFRs have become a key target of novel drugs in recent years for the treatment of neurological diseases. Notably, drug delivery systems can enhance the clinical therapeutic efficacy of these drugs. Aim of review This review highlights the critical role of FGFs/FGFRs in various neuroinflammatory diseases and provides an overview of the current research on FGFs/FGFRs-targeted therapeutic drugs, their novel delivery systems, and development potential. Advances in this field can enhance further application of potential drugs, offering new insights and approaches for treating neuroinflammatory diseases, thus reducing the incidence and progression. Key scientific concepts of review Moreover, this review summarizes the structure and function of FGFs/FGFRs, elucidates the signaling pathways through which the FGFs/FGFRs system is involved in neuroinflammatory diseases (Alzheimer's disease (AD) and Parkinson's disease (PD)), and emphasizes the key role of FGFs/FGFRs system in disease progression. Fur

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansAlzheimer DiseaseFibroblast Growth FactorsReceptors, Fibroblast Growth FactorDrug Delivery SystemsSignal TransductionNeuroinflammatory Diseases
NeuroinflammationChronic Inflammation
View on PubMedFull text on Europe PMCDOI

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

View all: topic “fgfs fgfrs neuroinflammatory”View all: author wangView all: year 2025

Related research